Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906131 | 0.90 | ATM (0.49) | ATMCYP2D6CYP3A4CHRM3ALDH1A1 | |
| SCHEMBL25987495 | 0.87 | CHRM3 (0.44) | ATMSMN1; SMN2CYP2D6CYP3A4CHRM3 | |
| SCHEMBL2370052 | 0.83 | ATM (0.69) | ATMSMN1; SMN2CYP2D6CYP3A4CHRM3 | |
| SCHEMBL2370044 | 0.83 | ATM (0.69) | ATMSMN1; SMN2CYP2D6CYP3A4CHRM3 | |
| SCHEMBL2434662 | 0.83 | ATM (0.69) | ATMSMN1; SMN2CYP2D6CYP3A4CHRM3 | |
| SCHEMBL25987491 | 0.82 | ATM (0.66) | ATMCHRM3 | |
| SCHEMBL9906133 | 0.79 | ATM (0.43) | ATMCHRM3CYP19A1 | |
| SCHEMBL18369775 | 0.77 | SMN1; SMN2 (0.43) | ATMSMN1; SMN2CYP2D6CYP3A4HTT | |
| SCHEMBL26220807 | 0.76 | SMN1; SMN2 (0.56) | ATMSMN1; SMN2CYP2D6CYP3A4POLB | |
| SCHEMBL13073268 | 0.76 | CYP19A1 (0.46) | SMN1; SMN2CYP2D6CHRM3CYP19A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | disclosed |
| US-8338424-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8198304-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8039489-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885SMN1; SMN2 3007/4885CYP2D6 2061/4885 |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885SMN1; SMN2 3007/4885CYP2D6 2061/4885 |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885SMN1; SMN2 3007/4885CYP2D6 2061/4885 |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885SMN1; SMN2 3007/4885CYP2D6 2061/4885 |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM1 | ATM 2759/4885SMN1; SMN2 3007/4885CYP2D6 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.